Navigation Links
IntelliCyt Introduces New System for Multiplexed Screening of Suspension Assays

Albuquerque, NM, (PRWEB) January 12, 2013

IntelliCyt Corporation, a provider of assay screening solutions for phenotypic drug discovery, antibody discovery and in vitro toxicity testing, today announced the introduction of their new iQue™ Screener. The new system is the latest addition to IntelliCyt’s platform of instrumentation, application-specific reagents, integrated multi-user analysis and informatics tools. The iQue Screener will be unveiled tomorrow at the Society for Laboratory Automation and Screening (SLAS) 2nd Annual Conference in Orlando, Florida.

“The iQue Screener is our next generation system, integrating IntelliCyt’s technology into an instrument that is ideal for the screening environment. Researchers can now evaluate compound effects on non-adherent cell lines, primary immune system cells and molecular interactions using cell or bead-based screening assays”, commented Terry Dunlay, CEO at IntelliCyt. “Laboratories will see a drastic reduction in time to final results and be able to generate higher quality and more reproducible data. Our early access customers have been very happy with the ease of use, workflow support and powerful data analysis capabilities the system provides.”

IntelliCyt’s screening systems for cell and bead-based assays are the first high-throughput, high-content bench top analyzers designed for rapid screening of cells and beads in suspension. Unlike other screening technologies that provide data on a per well basis, IntelliCyt’s technology provides information-rich data on a cell by cell basis in 96- and 384-well microplates. Micro-volume sample delivery combined with rapid sample processing and highly sensitive multiplexing capabilities let researchers in many fields screen large libraries at unprecedented speed and also drastically reduce costs.

About IntelliCyt Corporation

IntelliCyt Corporation develops innovative, high-throughput, high-content cell and bead-based screening solutions for use in phenotypic drug discovery, antibody discovery and in vitro toxicity testing. IntelliCyt’s proprietary technologies, instrumentation, assays and software products address the pervasive need to provide turnkey solutions that increase productivity in pharmaceutical, biotechnology, and life science research. For more information, please visit

IntelliCyt Corporation
Michael Sjaastad, Director of Business Development

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. iLuv Introduces a Range of Accessories to Enhance Apple’s Lightning Devices at 2013 CES
2. RURO Introduces the FreezerPro® ColdTrack RFID Kit
3. Zinman & Company Introduces Year-End Tax Review for Clients Using Virtual Controllership Services
4. White Mountain Process Introduces Squeal-less Mechanical Seal
5. AllCells Introduces Autoimmune Diseased Cells and Tissue Products
6. Vision Research Introduces the Newest Member Of the Phantom®- 1Mpx- v-Series Camera Family
7. JPSA Introduces Picosecond Laser Micromachining System
8. Profit Lifter for Pro Mold Removers: Molderizer Introduces Remediation Product Like No Other
9. WHEATON® Introduces a New Web Community for Scientists, Researchers, and Biopharmaceutical Packagers
10. NextGen introduces its first generation of animal biomarker products for development of brain disorder diagnostics
11. Leading Pharmaceutical Marketing Research and Consulting Company Introduces Intelligent Efficiency Program
Post Your Comments:
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... 23, 2016 , ... In a new case report published today in STEM ... who developed lymphedema after being treated for breast cancer benefitted from an injection of ... dealing with this debilitating, frequent side effect of cancer treatment. , Lymphedema ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
Breaking Biology News(10 mins):